Texas
LATEST FROM BIOSPACE
Please check out the biopharma industry’s COVID-19 stories that are trending for April 6, 2021.
A current Phase III trial of the Pfizer-BioNTech COVID-19 vaccine has confirmed the protection remains high for at least six months after the second dose. In a statement, Pfizer and BioNTech reported the vaccine was 91.3% effective against the disease.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Will We Need COVID-19 Vaccines Every Year? Although the jury is still out, a study out of Charité – Universitätsmedizin Berlin suggests that the answer is yes for a few years, but may be unnecessary after a few years post-pandemic.
New markets are emerging, and a new report from the market research team at JLL pinpoints some of these growing areas.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 16, 2021.
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson’s disease, Alzheimer’s, HIV and more.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.
Baylor College of Medicine researchers suggest that the analysis of all protein data from aggressive human cancers could help identify novel treatment targets.
PRESS RELEASES